While other reviews have described the MACE risk reduction in the general population with T2DM [23, 24], non-T2DM [25], or both [26], the present study seeks to address the gap in the literature in providing a comprehensive meta-analysis on the number need to treat (NNT), efficacy and safety profile of GLP-1RA in reducing the risk of myocardial infarction (MI) and individual ASCVD constituents, namely non-fatal MI, unstable angina, coronary revascularization, and/or cardiovascular mortality
Clinical reviews 3 of peptide-based therapies suggest that, regarding the brain-gut axis, BPC 157 has neuroprotective and muscle-recovery properties
A few - including individuals battling opioid dependence - described unprecedented periods of sobriety
Encourage open dialogue to address concerns, clarify expectations, and confirm understanding